Ikena Common Stock Shares Outstanding vs Non Currrent Assets Other Analysis

IKNA Stock

USD 1.29 0.06 4.44%

Ikena Oncology financial indicator trend analysis is infinitely more than just investigating Ikena Oncology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ikena Oncology is a good investment. Please check the relationship between Ikena Oncology Common Stock Shares Outstanding and its Non Currrent Assets Other accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.

Common Stock Shares Outstanding vs Non Currrent Assets Other

Common Stock Shares Outstanding vs Non Currrent Assets Other Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ikena Oncology Common Stock Shares Outstanding account and Non Currrent Assets Other. At this time, the significance of the direction appears to have strong relationship.

The correlation between Ikena Oncology's Common Stock Shares Outstanding and Non Currrent Assets Other is 0.71. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Ikena Oncology, assuming nothing else is changed. The correlation between historical values of Ikena Oncology's Common Stock Shares Outstanding and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Ikena Oncology are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Common Stock Shares Outstanding i.e., Ikena Oncology's Common Stock Shares Outstanding and Non Currrent Assets Other go up and down completely randomly.

Correlation Coefficient

0.71

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Most indicators from Ikena Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ikena Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.At present, Ikena Oncology's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 2.86, whereas Selling General Administrative is forecasted to decline to about 17.9 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	65.1M	86.5M	83.6M	70.7M
Cost Of Revenue	47.1M	2.0M	1.0M	969K

Total Operating Expenses Cost Of Revenue

Ikena Oncology fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Current Assets	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital
Other Current Liab		0.72	0.26	0.8	-0.91	0.02	0.65	0.91	0.65	0.97	0.9	-0.96	0.82	0.91	-0.78	-0.77	0.47	0.94	0.98	0.89	0.9	0.61	-0.6	0.91	-0.6	0.82
Total Current Liabilities	0.72		0.76	0.51	-0.61	-0.43	0.49	0.9	0.07	0.61	0.79	-0.82	0.56	0.63	-0.42	-0.8	0.62	0.61	0.65	0.79	0.55	0.27	-0.27	0.56	-0.26	0.56
Other Liab	0.26	0.76		-0.08	-0.17	-0.81	0.32	0.45	-0.44	0.16	0.24	-0.35	-0.02	0.06	-0.03	-0.34	0.28	0.08	0.17	0.25	0.03	0.03	0.24	0.03	0.24	-0.02
Net Tangible Assets	0.8	0.51	-0.08		-0.86	0.12	0.57	0.78	0.85	0.85	0.85	-0.73	1.0	0.96	-0.82	-0.65	0.43	0.95	0.88	0.83	0.94	0.66	-0.93	0.96	-0.93	1.0
Retained Earnings	-0.91	-0.61	-0.17	-0.86		0.05	-0.86	-0.8	-0.69	-0.91	-0.82	0.84	-0.88	-0.87	0.97	0.63	-0.3	-0.92	-0.95	-0.8	-0.87	-0.85	0.74	-0.91	0.75	-0.88
Accounts Payable	0.02	-0.43	-0.81	0.12	0.05		-0.22	-0.12	0.37	0.0	0.1	-0.05	0.08	0.07	0.02	-0.12	0.16	0.05	0.03	0.1	0.05	-0.03	-0.05	0.05	-0.05	0.08
Other Current Assets	0.65	0.49	0.32	0.57	-0.86	-0.22		0.59	0.38	0.63	0.57	-0.62	0.59	0.54	-0.89	-0.47	0.18	0.61	0.7	0.56	0.54	0.94	-0.45	0.61	-0.48	0.59
Total Current Assets	0.91	0.9	0.45	0.78	-0.8	-0.12	0.59		0.48	0.86	0.97	-0.95	0.81	0.88	-0.64	-0.92	0.73	0.87	0.89	0.97	0.83	0.49	-0.53	0.83	-0.52	0.81
Common Stock	0.65	0.07	-0.44	0.85	-0.69	0.37	0.38	0.48		0.78	0.6	-0.49	0.83	0.81	-0.71	-0.37	0.21	0.83	0.76	0.57	0.87	0.6	-0.86	0.86	-0.86	0.83
Property Plant Equipment	0.97	0.61	0.16	0.85	-0.91	0.0	0.63	0.86	0.78		0.85	-0.87	0.86	0.94	-0.81	-0.68	0.4	0.97	0.99	0.83	0.96	0.64	-0.71	0.96	-0.71	0.86
Total Assets	0.9	0.79	0.24	0.85	-0.82	0.1	0.57	0.97	0.6	0.85		-0.94	0.87	0.91	-0.67	-0.95	0.76	0.89	0.9	1.0	0.86	0.53	-0.6	0.86	-0.6	0.87
Short Long Term Debt Total	-0.96	-0.82	-0.35	-0.73	0.84	-0.05	-0.62	-0.95	-0.49	-0.87	-0.94		-0.75	-0.85	0.68	0.89	-0.62	-0.85	-0.91	-0.94	-0.8	-0.52	0.45	-0.81	0.45	-0.75
Total Stockholder Equity	0.82	0.56	-0.02	1.0	-0.88	0.08	0.59	0.81	0.83	0.86	0.87	-0.75		0.97	-0.83	-0.68	0.45	0.96	0.9	0.85	0.95	0.66	-0.92	0.96	-0.92	1.0
Property Plant And Equipment Net	0.91	0.63	0.06	0.96	-0.87	0.07	0.54	0.88	0.81	0.94	0.91	-0.85	0.97		-0.78	-0.73	0.5	0.99	0.95	0.9	0.99	0.58	-0.84	0.98	-0.84	0.97
Current Deferred Revenue	-0.78	-0.42	-0.03	-0.82	0.97	0.02	-0.89	-0.64	-0.71	-0.81	-0.67	0.68	-0.83	-0.78		0.45	-0.12	-0.83	-0.85	-0.65	-0.79	-0.93	0.77	-0.84	0.79	-0.83
Net Debt	-0.77	-0.8	-0.34	-0.65	0.63	-0.12	-0.47	-0.92	-0.37	-0.68	-0.95	0.89	-0.68	-0.73	0.45		-0.91	-0.71	-0.75	-0.96	-0.67	-0.38	0.34	-0.67	0.33	-0.68
Cash	0.47	0.62	0.28	0.43	-0.3	0.16	0.18	0.73	0.21	0.4	0.76	-0.62	0.45	0.5	-0.12	-0.91		0.44	0.46	0.78	0.44	0.12	-0.13	0.42	-0.12	0.45
Non Current Assets Total	0.94	0.61	0.08	0.95	-0.92	0.05	0.61	0.87	0.83	0.97	0.89	-0.85	0.96	0.99	-0.83	-0.71	0.44		0.98	0.88	0.99	0.66	-0.83	1.0	-0.83	0.96
Non Currrent Assets Other	0.98	0.65	0.17	0.88	-0.95	0.03	0.7	0.89	0.76	0.99	0.9	-0.91	0.9	0.95	-0.85	-0.75	0.46	0.98		0.89	0.96	0.71	-0.72	0.97	-0.72	0.9
Cash And Short Term Investments	0.89	0.79	0.25	0.83	-0.8	0.1	0.56	0.97	0.57	0.83	1.0	-0.94	0.85	0.9	-0.65	-0.96	0.78	0.88	0.89		0.84	0.51	-0.57	0.84	-0.57	0.85
Common Stock Total Equity	0.9	0.55	0.03	0.94	-0.87	0.05	0.54	0.83	0.87	0.96	0.86	-0.8	0.95	0.99	-0.79	-0.67	0.44	0.99	0.96	0.84		0.62	-0.85	1.0	-0.85	0.95
Common Stock Shares Outstanding	0.61	0.27	0.03	0.66	-0.85	-0.03	0.94	0.49	0.6	0.64	0.53	-0.52	0.66	0.58	-0.93	-0.38	0.12	0.66	0.71	0.51	0.62		-0.6	0.68	-0.63	0.66
Non Current Liabilities Total	-0.6	-0.27	0.24	-0.93	0.74	-0.05	-0.45	-0.53	-0.86	-0.71	-0.6	0.45	-0.92	-0.84	0.77	0.34	-0.13	-0.83	-0.72	-0.57	-0.85	-0.6		-0.86	1.0	-0.92
Other Stockholder Equity	0.91	0.56	0.03	0.96	-0.91	0.05	0.61	0.83	0.86	0.96	0.86	-0.81	0.96	0.98	-0.84	-0.67	0.42	1.0	0.97	0.84	1.0	0.68	-0.86		-0.86	0.96
Total Liab	-0.6	-0.26	0.24	-0.93	0.75	-0.05	-0.48	-0.52	-0.86	-0.71	-0.6	0.45	-0.92	-0.84	0.79	0.33	-0.12	-0.83	-0.72	-0.57	-0.85	-0.63	1.0	-0.86		-0.92
Net Invested Capital	0.82	0.56	-0.02	1.0	-0.88	0.08	0.59	0.81	0.83	0.86	0.87	-0.75	1.0	0.97	-0.83	-0.68	0.45	0.96	0.9	0.85	0.95	0.66	-0.92	0.96	-0.92

Click cells to compare fundamentals

Ikena Oncology Account Relationship Matchups

Ikena Oncology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	121K	5.4M	5.9M	8.3M	8.6M	5.2M
Total Current Liabilities	24.3M	28.3M	27.2M	21.5M	14.2M	21.9M
Net Tangible Assets	(61.5M)	(101.0M)	207.9M	147.0M	169.0M	177.5M
Retained Earnings	(67.1M)	(111.3M)	(145.5M)	(214.2M)	(282.4M)	(268.3M)
Accounts Payable	935K	2.1M	2.4M	2.1M	2.1M	2.2M
Other Current Assets	1.3M	1.6M	629K	964K	3.2M	3.4M
Total Current Assets	85.2M	166.0M	236.5M	160.0M	178.7M	155.2M
Property Plant Equipment	769K	1.6M	2.4M	3.2M	3.7M	1.9M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Ikena Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ikena Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ikena Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ikena Oncology Stock:

How To Invest In Ikena

Details

Is Ikena Stock a good investment?

Details

What is Ikena Oncology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.

You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Ikena Stock analysis

When running Ikena Oncology's price analysis, check to measure Ikena Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ikena Oncology is operating at the current time. Most of Ikena Oncology's value examination focuses on studying past and present price action to predict the probability of Ikena Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ikena Oncology's price. Additionally, you may evaluate how the addition of Ikena Oncology to your portfolios can decrease your overall portfolio volatility.

	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance

Is Ikena Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.63)

Revenue Per Share

0.219

Quarterly Revenue Growth

(0.88)

Return On Assets

(0.26)

Return On Equity

(0.43)

The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ikena Common Stock Shares Outstanding vs Non Currrent Assets Other Analysis

Common Stock Shares Outstanding vs Non Currrent Assets Other

Common Stock Shares Outstanding vs Non Currrent Assets Other Correlation Analysis

Correlation Coefficient

Common Stock Shares Outstanding

Non Currrent Assets Other

Ikena Oncology fundamental ratios Correlations

Ikena Oncology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ikena Oncology fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Ikena Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Net Tangible Assets
Net Invested Capital	+ 1.0	Net Tangible Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Other Stockholder Equity	+ 1.0	Non Current Assets Total
Other Stockholder Equity	+ 1.0	Common Stock Total Equity

Cash And Short Term Investments	- 0.96	Net Debt
Short Long Term Debt Total	- 0.96	Other Current Liab
Net Debt	- 0.95	Total Assets
Short Long Term Debt Total	- 0.95	Total Current Assets
Non Currrent Assets Other	- 0.95	Retained Earnings
Cash And Short Term Investments	- 0.94	Short Long Term Debt Total